glp-1 receptor agonists and cancer risk in adults with obesity confer 'modest' protection against obesity-related cancers GLP1 Receptor Agonists—Effects beyond Obesity
Description
Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug
Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery
Tiered Evidence: Tier 1 - what the trials actually show ObesityThe strongest evidence is in obesity
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP
doi: 10.1056/NEJMoa2206038 83 US National Institutes of Health
Atherosclerosisan inflammatory disease
